These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27640816)

  • 1. Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects.
    Borgs L; Peyre E; Alix P; Hanon K; Grobarczyk B; Godin JD; Purnelle A; Krusy N; Maquet P; Lefebvre P; Seutin V; Malgrange B; Nguyen L
    Sci Rep; 2016 Sep; 6():33377. PubMed ID: 27640816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.
    Qing X; Walter J; Jarazo J; Arias-Fuenzalida J; Hillje AL; Schwamborn JC
    Stem Cell Res; 2017 Oct; 24():44-50. PubMed ID: 28826027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.
    Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG
    Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
    Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
    Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.
    Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurite Collapse and Altered ER Ca
    Korecka JA; Talbot S; Osborn TM; de Leeuw SM; Levy SA; Ferrari EJ; Moskites A; Atkinson E; Jodelka FM; Hinrich AJ; Hastings ML; Woolf CJ; Hallett PJ; Isacson O
    Stem Cell Reports; 2019 Jan; 12(1):29-41. PubMed ID: 30595548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
    Kim J; Daadi MM
    Brain Res; 2019 Nov; 1722():146342. PubMed ID: 31330122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
    Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
    Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease.
    de Rus Jacquet A; Tancredi JL; Lemire AL; DeSantis MC; Li WP; O'Shea EK
    Elife; 2021 Sep; 10():. PubMed ID: 34590578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
    Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
    PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene.
    Marote A; Pomeshchik Y; Collin A; Goldwurm S; Lamas NJ; Pinto L; Salgado AJ; Roybon L
    Stem Cell Res; 2018 Apr; 28():44-47. PubMed ID: 29414418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.
    Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH
    Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis.
    Kim JW; Yin X; Jhaldiyal A; Khan MR; Martin I; Xie Z; Perez-Rosello T; Kumar M; Abalde-Atristain L; Xu J; Chen L; Eacker SM; Surmeier DJ; Ingolia NT; Dawson TM; Dawson VL
    Cell Stem Cell; 2020 Oct; 27(4):633-645.e7. PubMed ID: 32846140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations.
    Oleksy C; Massart F; Goldwurm S; Arado A; Arena G; Boussaad I; Krüger R
    Stem Cell Res; 2023 Oct; 72():103212. PubMed ID: 37832355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
    Vermilyea SC; Emborg ME
    Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
    Schwab AJ; Ebert AD
    Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
    Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients.
    Nickels SL; Walter J; Bolognin S; Gérard D; Jaeger C; Qing X; Tisserand J; Jarazo J; Hemmer K; Harms A; Halder R; Lucarelli P; Berger E; Antony PMA; Glaab E; Hankemeier T; Klein C; Sauter T; Sinkkonen L; Schwamborn JC
    Parkinsonism Relat Disord; 2019 Oct; 67():48-55. PubMed ID: 31621607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.